A few days ago, the National Bureau of Statistics announced the performance of China's economy in the first three quarters. The pharmaceutical manufacturing industry grew by 3.1 in the first three quarters, which was lower than the year-on-year growth rate of the national industrial value added above designated size (5.8) in the first three quarters, and also lower than the year-on-year growth rate of manufacturing (6%), and the year-on-year growth rate of high-tech manufacturing (9.1).

Pharmaceutical stocks three quarterly report disclosure is about to enter the climax, from the company that has released the three quarterly report, the performance differentiation is obvious. As of October 24, 63 listed pharmaceutical companies have issued three quarterly reports, of which 37 have achieved positive revenue growth and 26 have declined. In the third quarter alone, the operating income of 29 companies increased month-on-month, while 34 companies declined month-on-month.

In terms of net profit, 34 achieved positive growth and 29 declined. In a single quarter, there were 30 companies that grew month-on-month and 33 companies that declined month-on-month.

In the first half of 2024, the blood products in the biological products category, high-value consumables in the medical device category, chemical preparations, raw materials and other sectors performed relatively well. In the third quarter, this momentum continued.